GlassScriptPhysician profile
Jonathan D Ruzi
NPI 1093708935
$6,584.39
in general payments reported to CMS, 2019-2025
39 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $702 · 2021: $619 · 2022: $655 · 2023: $1,242 · 2024: $1,062 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,883 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,882.89 |
| Education | $229.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $815.02 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $784.00 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Insmed, INC. | $624.49 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $462.23 | 2019-2025 | |
| United Therapeutics Corporation | $328.62 | 2021-2025 | Tyvaso, Tyvaso |
| Jazz Pharmaceuticals INC. | $327.19 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.17 | 2019-2025 | |
| Viiv Healthcare Company | $255.47 | 2024-2025 | Dovato, Rukobia |
| Inspire Medical Systems, INC. | $235.38 | 2020-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $225.35 | 2020-2025 | Dupixent |
| Intuitive Surgical, INC. | $224.76 | 2023 | |
| Astellas Pharma US INC | $218.83 | 2024-2025 | Cresemba, Ambisome |
| Grifols USA, LLC | $209.42 | 2020-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $175.59 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $148.41 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $137.65 | 2019-2025 | Zerbaxa, Recarbrio, Prevymis |
| Mayne Pharma Commercial LLC | $132.21 | 2019-2021 | |
| Amgen INC. | $117.11 | 2022-2025 | Tezspire |
| Viatris Specialty LLC | $108.08 | 2025 | Yupelri |
| Covis Pharma Gmbh | $100.03 | 2021-2022 | |
| Verona Pharma, INC. | $97.84 | 2025 | Ohtuvayre |
| Electromed, INC. | $93.02 | 2024-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $73.77 | 2021-2023 | Glassia |
| Csl Behring | $50.54 | 2023-2024 | Kcentra |
| Pfizer INC. | $41.14 | 2022-2023 | |
| Gilead Sciences, INC. | $40.03 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $37.05 | 2021 | |
| Baxter Healthcare | $32.50 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Paratek Pharmaceuticals, INC. | $23.29 | 2020 | |
| Advanced Respiratory, INC | $22.88 | 2020-2021 | |
| Boston Scientific Corporation | $22.55 | 2021 | |
| Shionogi INC | $21.03 | 2022 | |
| Circassia INC. | $20.06 | 2019 | |
| Philips North America LLC | $18.66 | 2020 | |
| Napo Pharmaceuticals INC | $17.16 | 2025 | Mytesi |
| Avadel Cns Pharmaceuticals, LLC | $16.84 | 2025 | Lumryz |
| Pulmonx Corporation | $13.34 | 2019 | |
| Eisai INC. | $12.80 | 2021 | |
| 3b Medical, INC. | $9.88 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ruzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.